Quince Therapeutics (QNCX) Stock Price, News & Analysis

Company Overview

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $30.00 to $31.88
• 50-Day Range: $16.75 to $34.57
• 52-Week Range: $15.10 to $909.98
• Volume: 5,196 shs
• Average Volume: 216,753 shs
• Market Capitalization: $30.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $260.00
• Consensus Rating: Hold

Quince Therapeutics Stock Analysis - MarketRank™

Quince Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 400th out of 906 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Quince Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.42, and is based on 2 strong buy ratings, 3 buy ratings, 5 hold ratings, and 2 sell ratings.

Upside Potential

Quince Therapeutics has a consensus price target of $260.00, representing about 773.8% upside from its current price of $29.76.

Amount of Analyst Coverage

Quince Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Quince Therapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Quince Therapeutics is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.38% of the float of Quince Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Quince Therapeutics has a short interest ratio ("days to cover") of 1.73, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Quince Therapeutics has recently increased by 6.44%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Quince Therapeutics does not currently pay a dividend.

Dividend Growth

Quince Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.99

News Sentiment

Quince Therapeutics has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Quince Therapeutics this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for QNCX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

5 people have added Quince Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Quince Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.60% of the stock of Quince Therapeutics is held by insiders.

Percentage Held by Institutions

30.75% of the stock of Quince Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/08/2026
• 12th Annual Cantor Fitzgerald Global Healthcare Conference: 9/09/2026
• H.C. Wainwright 28th Annual Global Investment Conference: 9/14/2026
• EGM 2026: 10/06/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:QNCX
• Previous Symbol: NASDAQ:CRTX
• CIK: 1662774
• Web: www.quincetx.com
• Phone: (650) 910-5717
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Quince Therapeutics: $260.00
• High Price Target: $1,000.00
• Low Price Target: $68.00
• Potential Upside/Downside: +773.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.42
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($156.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$83.98 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -133.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.52
• Quick Ratio: 14.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($128.18) per share
• Price / Book: -0.23

Miscellaneous

• Outstanding Shares: 1,020,000
• Free Float: 960,000
• Market Cap: $30.35 million
• Optionable: Optionable
• Beta: 1.31